Scarica l'app Stockscreener
14.90
2.83%
0.41
Dopo l'orario di chiusura:
14.90
Precedente Chiudi:
$14.49
Aprire:
$14.43
Volume 24 ore:
280.96K
Relative Volume:
0.75
Capitalizzazione di mercato:
$905.94M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-5.438
EPS:
-2.74
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
+1.22%
1M Prestazione:
+29.23%
6M Prestazione:
+6.58%
1 anno Prestazione:
-7.51%
Intervallo 1D:
$14.12
$15.07
Intervallo di 1 settimana:
$14.00
$15.25
Portata 52W:
$10.22
$19.62
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-18 | Iniziato | Canaccord Genuity | Buy |
| 2023-04-13 | Iniziato | Robert W. Baird | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-07 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Outperform |
| 2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-20 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Cowen | Outperform |
| 2020-06-29 | Iniziato | Needham | Buy |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat
SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News
Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle
An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily
The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
How To Trade (PLRX) - Stock Traders Daily
Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat
Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com
Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India
Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World
Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex
American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs - GlobeNewswire
Lululemon Athletica (LULU-Q) QuotePress Release - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLC - Defense World
Ensign Peak Advisors Inc Grows Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Bakersfield Californian
11,678 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Acquired by Deerfield Management Company L.P. Series C - Defense World
Pliant Therapeutics updates bylaws, aligns with Delaware law By Investing.com - Investing.com South Africa
Pliant Therapeutics updates bylaws, aligns with Delaware law - Investing.com
Investing in Pliant Therapeutics Inc (PLRX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Pliant Therapeutics Inc (PLRX) receives an Outperform rating from Leerink Partners - Knox Daily
Pharma stock to buy now for an upside of 20%; Are you holding it? - Trade Brains
5,372 Shares in Piper Sandler Companies (NYSE:PIPR) Purchased by Intech Investment Management LLC - MarketBeat
Berkley W R Corp Cuts Stock Position in Plum Acquisition Corp. I (NASDAQ:PLMI) - Defense World
Great Point Partners LLC Raises Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Priority Technology (NASDAQ:PRTH) Reaches New 1-Year High After Analyst Upgrade - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
First Light Asset Management LLC Sells 133,780 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Palfinger (OTCMKTS:PLFRY) Trading Down 2% - Defense World
Pulse Biosciences (NASDAQ:PLSE) Shares Down 5.4% - MarketBeat
Pulse Biosciences Inc [PLSE] Investment Appeal on the Rise - Knox Daily
Precigen Inc (PGEN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Rhumbline Advisers Raises Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Inspire Investing LLC Sells 8,725 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to "Sell" - MarketBeat
Piper Sandler Companies (NYSE:PIPR) Shares Acquired by Commonwealth Equity Services LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pliant Therapeutics Inc Azioni (PLRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hull Hans | Chief Business Officer |
Jul 10 '24 |
Sale |
11.56 |
9,900 |
114,444 |
227,494 |
| Cummings Keith Lamont | Chief Financial Officer |
Jul 10 '24 |
Sale |
11.56 |
10,911 |
126,131 |
282,115 |
| Coulie Bernard | President and CEO |
Jul 10 '24 |
Sale |
11.56 |
38,710 |
447,488 |
482,936 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jul 10 '24 |
Sale |
11.56 |
7,656 |
88,503 |
94,044 |
| Cummings Keith Lamont | Chief Financial Officer |
May 02 '24 |
Option Exercise |
2.08 |
21,000 |
43,680 |
271,713 |
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '24 |
Sale |
17.23 |
9,781 |
168,527 |
194,605 |
| Hull Hans | Chief Business Officer |
Jan 17 '24 |
Sale |
17.23 |
9,786 |
168,613 |
185,069 |
| Coulie Bernard | President and CEO |
Jan 17 '24 |
Sale |
17.23 |
25,721 |
443,173 |
316,382 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '24 |
Sale |
17.23 |
10,295 |
177,383 |
156,920 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '24 |
Sale |
17.23 |
5,197 |
89,544 |
55,246 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):